Arcutis Biotherapeutics ARQT 深 沪
等待开盘 09-16 09:30:00 美东时间
23.51
-0.760
-3.13%
华盛通- 最 高24.28
- 今 开24.23
- 成交量 345.93万股
- 最 低 23.10
- 昨 收 24.27
- 总市值 29.55亿
- 52周最高 31.77
- 市盈率 静 --
- 换手率 2.75%
- 52周最低 17.67
- 委 比 -42.64%
- 总股本 1.26亿
- 历史最高 40.88
- 量 比 1.36
- 振 幅 4.86%
- 历史最低 1.76
- 每 手 1
- 风险率 3.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多The Trade Desk to leave S&P 500 as Bloom Energy, Everpure, Illumina join index
S&P Dow Jones Indices on Friday said it will add Bloom Energy (BE), Everpure (P) and Illumina (ILMN) to the S&P 500 as part of a broad quarterly rebalancing scheduled to take effect before trading ope...
09-06 21:15
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 57,000 restricted stock units to 11 new employees under its 2022 Inducement Plan, vesting over four years. The company focuses on developing innovative treatments for chronic inflammatory skin diseases.
09-04 20:00
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced that its management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14-16, 2026. A fireside chat is scheduled for September 16 at 1:50 p.m. ET. The company, focused on immuno-dermatology innovations, has developed treatments for major inflammatory skin diseases. A replay of the webcast will be available on its website for 180 days. For more...
09-02 20:00
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
Oruka Therapeutics appoints Todd Edwards as Chief Commercial Officer. With over 25 years of experience in immunology and dermatology, Edwards joins from Arcutis where he led successful commercial transformations. Oruka aims to advance its biologics for chronic skin diseases like plaque psoriasis and hidradenitis suppurativa. Edwards' leadership is expected to strengthen the company's commercial capabilities.
08-24 20:01
Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
Health Canada approval of new 0.05% cream formulation expands the ZORYVE portfolio to include a once-daily, steroid-free option for younger children The 0.05% formulation was specifically selected for young children, with clinical studies demonstrating significant improvements in disease severity as...
08-21 01:47
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 24 new employees 143,500 RSUs and options for 37,000 shares under its 2022 Inducement Plan, effective August 3, 2026. RSUs vest over four years, with 25% annually. Stock options vest similarly, with 25% after one year and the remainder in monthly installments over three years, at an exercise price of $25.94 per share. Arcutis, a medical dermatology company, focuses on innovative treatments for chronic inflammatory ...
08-07 20:00
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
08-06 21:28
美股夜盘 | SoundHound AI暴升22.55%，Paycom Software暴升12.24%
BillionToOne暴泻27.66%；Fluence Energy暴泻22.84%；HubSpot急泻19.67%
08-06 08:06
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
08-06 04:50
